Pharmacological treatment of chronic heart failure

被引：0
作者：
Rachele Adorisio
Leonardo De Luca
Joseph Rossi
Mihai Gheorghiade
机构：
[1] Ospedale Bambino Gesù,Department of Cardiology and Cardiac Surgery
[2] European Hospital,Division of Cardiology
[3] Northwestern University,undefined
[4] Feinberg School of Medicine,undefined
[5] Northwestern University,undefined
[6] Feinberg School of Medicine,undefined
来源：
Heart Failure Reviews | 2006年 / 11卷
关键词：
Heart failure; Drugs; Angiotensin-converting enzyme inhibitors; β-blockers; Diuretics; Digitalis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.
引用
收藏
页码：109 / 123
页数：14
相关论文
共 496 条
  • [61] Chatterjee K(2000)Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study, ELITE II Lancet 355 1582-7
  • [62] Parmley WW(2001)A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Engl J Med 345 1667-1675
  • [63] Swedberg K(2002)Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Lancet 360 752-60
  • [64] Atherton B(1999)Candesartan in heart failure- assessment of reduction in mortality and morbidity (CHARM): rationale and design J Card Fail 5 276-82
  • [65] Curran D(2003)Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 777-81
  • [66] Cucci M(2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 772-6
  • [67] Konstam MA(2003)Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767-71
  • [68] Rousseau MF(2003)Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893-906
  • [69] Kronenberg MW(2000)Pharmacology of diuretics Am J Med Sci 319 38-50
  • [70] Udelson JE(1994)Oral torsemide in patients with chronic congestive heart failure: effects on bodyweight, edema, and electrolyte excretion: torsemide Investigators Group Pharmacotherapy 14 514-21
234567891011